Answers are grounded in this paper and cite their sources.
Phase I trial evaluates safety and pharmacokinetics of bisnorcymserine in adults, suggesting potential for Alzheimer's treatment.
(SD) were 1.8 (1.0-5.0) hr and 13.94 (7.64) ng/mL for the 40 mg dose, 1.8 (1.5-5.0) hr and 18.54 (6.44) ng/mL for the 80 mg dose, and 2 (1.0-4.5) hr and 20.93 (5.00) ng/mL for the 120 mg dose. The mean half-life of BNC ranged from 5.5 to 7 h. BNC was safe and well tolerated when administered as a single oral dose of up to 120 mg. This first-in-human, phase I study permits further investigation of this drug as a potential symptomatic treatment for AD. ClinicalTrials.gov, NCT01747213.
No takes yet. Share an insight, caveat, or question.
Tzieras et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: